Medicus Pharma Ltd. Commo... (MDCX)
| Bid | 4.38 |
| Market Cap | 50.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.16M |
| EPS (ttm) | -1.16 |
| PE Ratio (ttm) | -3.66 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.95 |
| Volume | 27,156 |
| Avg. Volume (20D) | 67,670 |
| Open | 4.45 |
| Previous Close | 4.27 |
| Day's Range | 4.16 - 4.55 |
| 52-Week Range | 1.80 - 4.99 |
| Beta | 5.56 |
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer....
Analyst Forecast
According to 2 analyst ratings, the average rating for MDCX stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 182.35% from the latest price.
Stock Forecasts
1 week ago · proactiveinvestors.com
Medicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatmentMedicus Pharma (NASDAQ:MDCX) announced that it has entered into a binding letter of intent to acquire Antev, a clinical-stage biotechnology firm developing a first-in-market product Teverelix for acut...
2 weeks ago · proactiveinvestors.com
Medicus Pharma expands basal cell carcinoma study after encouraging early dataMedicus Pharma (NASDAQ:MDCX) said it has received approval from an Institutional Review Board (IRB) to increase the number of participants in its ongoing Phase 2 clinical trial of a novel non-invasive...
1 month ago · newsfilecorp.com
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A OfferingPhiladelphia, Pennsylvania--(Newsfile Corp. - March 10, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of its previously announced Tier II Regulation A offering...
2 months ago · proactiveinvestors.com
Medicus Pharma CEO discusses latest skin cancer trial results - ICYMIMedicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the latest progress in the company's ongoing clinical trials for its innovative skin cancer treatment. The company is developi...
2 months ago · proactiveinvestors.com
Medicus Pharma unveils pricing of financing to advance skin cancer treatmentMedicus Pharma (NASDAQ:MDCX) has announced the pricing of its Tier II Regulation A offering, aiming to raise approximately $4.2 million through the sale of 1.49 million units at $2.80 per unit. Each u...
2 months ago · newsfilecorp.com
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A OfferingPhiladelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its Tier II Regulation A offering of 1,490,000 units, o...
2 months ago · proactiveinvestors.com
Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim resultsMedicus Pharma (NASDAQ:MDCX) has revealed interim results from its Phase 2 clinical trial for a non-invasive treatment targeting basal cell carcinoma (BCC) showing promising efficacy and safety outcom...
